11 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 15 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 11, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
Follow Lymphangioleiomyomatosis: new trials by email Literature Review of Lymphangioleiomyomatosis trials Research Report on Lymphangioleiomyomatosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Loratadine in Lymphangioleiomyomatosis Loratadine, Placebo 10mg/day added to rapamycin for 12 months - Lymphangioleiomyomatosis | Phase 2 | Unknown | Institut d'Investigació Biomèdica de Bellvitge | 62 | 2021-11-01 | 2022-01-27 |
| Feasibility of [11C]Acetate-PET in LAM and TSC [11C]acetate - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Active not recruiting | Brigham and Women's Hospital | 7 | 2021-08-30 | 2026-01-21 |
| Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Sirolimus, Resveratrol - Lymphangioleiomyomatosis | Phase 2 | Completed | University of Cincinnati | 25 | 2018-03-31 | 2023-02-01 |
| LAM Pilot Study With Imatinib Mesylate Imatinib Mesylate 400Mg Capsule, Placebo - Capsule - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 18 | 2018-01-23 | 2020-06-16 |
| Discovery of Sirolimus Sensitive Biomarkers in Blood Sirolimus 2mg - Lymphangioleiomyomatosis | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 33 | 2017-12-04 | 2026-02-18 |
| A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) Nintedanib - Lymphangioleiomyomatosis | Phase 2 | Completed | IRCCS Multimedica | 30 | 2016-12-06 | 2022-09-28 |
| COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC Celecoxib - Lymphangioleiomyomatosis (LAM) | Phase 2 | Completed | Brigham and Women's Hospital | 12 | 2016-06-15 | 2022-01-20 |
| Safety of Simvastatin in LAM and TSC Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 10 | 2014-03-01 | 2020-08-25 |
| Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis albuterol inhaler, albuterol nebulizer, PFT - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 100 | 2013-06-10 | 2026-11-05 |
| Letrozole for Lymphangioleiomyomatosis Letrozole, Placebo - Lymphangioleiomyomatosis | Phase 2 | Completed | University of Cincinnati | 17 | 2011-05-01 | 2024-04-17 |
| A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis Everolimus - Lymphangioleiomyomatosis | Phase 2 | Completed | Novartis Pharmaceuticals | 24 | 2010-01-01 | 2020-11-19 |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM sirolimus - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 2 | Unknown | Cardiff University | 14 | 2005-10-01 | 2008-04-30 |
| RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM RAD001 - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 36 | 2005-08-01 | 2013-09-25 |
| Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM Rapamycin, sirolimus - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 25 | 2002-12-01 | 2007-04-09 |
| Treatment With Octreotide in Patients With Lymphangioleiomyomatosis Octreotide - Lymphangioleiomyomatosis, Lymphangiomyomas | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 4 | 2000-06-01 | 2010-04-30 |
Tuberous Sclerosis (5) · Ascites (1) · Chylothorax (1) · Chylous Ascites (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lymphangiomyoma (1) · Pleural Effusion (1)
Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoproliferative Disorders (15) · Neoplasm, Lymphatic Tissue (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms, Connective and Soft Tissue (15) · Perivascular Epithelioid Cell Neoplasms (15) · Lymphangiomyoma (14) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hamartoma (5)
Sirolimus (5) · Everolimus (3) · Celecoxib (1) · Imatinib Mesylate (1) · Letrozole (1) · Loratadine (1) · Octreotide (1) · Resveratrol (1) · Simvastatin (1) · Sugars (1) · carbon-11 acetate (1) · nintedanib (1)
National Heart, Lung, and Blood Institute (NHLBI) (3) · Brigham and Women's Hospital (2) · Children's Hospital Medical Center, Cincinnati (2) · University of Cincinnati (2) · Cardiff University (1) · IRCCS Multimedica (1) · Institut d'Investigació Biomèdica de Bellvitge (1) · Medical University of South Carolina (1) · Novartis Pharmaceuticals (1) · University of Pennsylvania (1)
United States (12) · Italy (2) · France (1) · Spain (1) · United Kingdom (1)
Joel Moss, M.D. (2) · Carmen P Priolo, MD PhD (1) · Christopher Meinberg (1) · David J Kwiatkowski, MD PhD (1) · Francis X McCormack, MD (1) · Frank McCormack, MD (1) · John Bissler, MD (1) · John J. Bissler, M.D. (1) · Julian R Sampson, DM (1) · Maria Molina-Molina, MD, PhD (1) · Maryl Kreider, MD, MSCE (1) · Nishant Gupta, MD (1) · Sergio A Harari, MD (1) · Vera P Krymskaya, PhD, MBA (1)
PMID 12172553, PMID 18184959, PMID 21410393, PMID 21482669, PMID 21525172, PMID 24556663, PMID 24591665, PMID 26113676, PMID 28570161, PMID 32060062, PMID 36642366, PMID 39489895
R21CA103486 (1), R34HL138235 (1)